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Abstract
The EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids was requested
to evaluate the genotoxic potential of one ﬂavouring substance from subgroup 1.1.1(b) of FGE.19 in
the Flavouring Group Evaluation 226 (FGE.226). The ﬂavour industry provided genotoxicity studies for
the substance 4,5-epoxydec-2(trans)-enal [FL-no: 16.071]. Based on these data, the Panel concluded
in FGE.226 that 4,5-epoxydec-2(trans)-enal did not induce gene mutations in bacterial cells but was
positive in an in vitro micronucleus assay, so, 4,5-epoxydec-2(trans)-enal is considered an in vitro
genotoxic agent. The negative results obtained in an in vivo micronucleus assay cannot overrule the
positive results of the in vitro micronucleus assay with and without S9-mix due to the lack of
demonstration of bone marrow exposure. Following this, the ﬂavour industry has provided plasma
analysis of a satellite group of rats treated with 4,5-epoxydec-2(trans)-enal in order to investigate the
systemic exposure of animals in the in vivo micronucleus assay. However, the plasma analysis did not
provide enough evidence of target tissue exposure. An in vivo Comet assay in rodents was
recommended in FGE.226, in order to investigate possible genotoxic effects at the ﬁrst site of contact
(e.g. stomach/duodenum cells) and in the liver. An in vivo Comet assay in liver and duodenum was
provided that suggests that 4,5-epoxydec-2(trans)-enal [FL-no: 16.071] did not induce DNA damage in
the duodenum of rats. However, the genotoxic effect observed in vitro was conﬁrmed in the in vivo
Comet assay in the liver of rats. The Panel concluded that 4,5-epoxydec-2(trans)-enal [FL-no: 16.071]
does raise a safety concern with respect to genotoxicity and, therefore, it cannot be evaluated
according to the Procedure.
© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
Following a request from the European Commission, the EFSA Panel on Food Contact Materials,
Enzymes, Flavourings and Processing Aids (CEF) was asked to deliver a scientiﬁc opinion on the
implications for human health of chemically deﬁned ﬂavouring substances used in or on foodstuffs in
the Member States. In particular, the Panel was asked to evaluate ﬂavouring substances using the
Procedure as referred to in the Commission Regulation (EC) No 1565/2000 (hereafter ‘the Procedure’).
The Union List of ﬂavourings and source materials was established by Commission Implementing
Regulation (EC) No 872/2012. The list contains ﬂavouring substances for which the scientiﬁc
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/2000.
The Flavouring Group Evaluation 226 (FGE.226), corresponding to subgroup 1.1.1(b) of FGE.19,
concerns one a,b-unsaturated aldehyde which is also an epoxide, 4,5-epoxydec-2(trans)-enal [FL-no:
16.071]. These structural elements are considered to be structural alerts for genotoxicity and the data
on genotoxicity previously available did not rule out the concern for genotoxicity.
To evaluate the genotoxic potential of 4,5-epoxydec-2(trans)-enal [FL-no: 16.071], the Panel has
therefore requested additional genotoxicity data according to the test strategy worked out by the
Panel.
According to the above requirements, the Industry has submitted genotoxicity studies for 4,5-
epoxydec-2(trans)-enal. Based on these data the Panel noted, in FGE.226, that 4,5-epoxydec-2(trans)-
enal did not induce gene mutations in bacterial cells, but was positive in an in vitro micronucleus
assay, so, 4,5-epoxydec-2(trans)-enal is considered an in vitro genotoxic agent. The negative results
obtained in an in vivo micronucleus assay cannot overrule the positive results of the in vitro
micronucleus assay with and without S9-mix due to the lack of cytotoxicity in the bone marrow. On
this basis, an in vivo Comet assay in rodents was recommended in order to investigate possible
genotoxic effects at the ﬁrst site of contact (e.g. stomach/duodenum cells) and in liver.
Subsequently, the ﬂavour industry has provided plasma analysis of a satellite group of rats treated
with 4,5-epoxydec-2(trans)-enal in order to investigate the systemic exposure of animals in the in vivo
micronucleus assay and an in vivo Comet assay in liver and duodenum.
The Panel concluded that the plasma analysis did not provide enough evidence of target tissue
exposure.
Comet assay data provided suggest that 4,5-epoxydec-2(trans)-enal [FL-no: 16.071] did not induce
DNA damage in the duodenum of rats treated up to 300 mg/kg body weight (bw) per day by oral
route (an estimate of the maximum tolerated dose in male rats). However, the genotoxic effect
observed in vitro was conﬁrmed in an in vivo comet assay in the liver of rats.
Overall, the Panel concluded that 4,5-epoxydec-2(trans)-enal [FL-no: 16.071] does raise a safety
concern with respect to genotoxicity, and therefore, it cannot be evaluated according to the Procedure.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
The use of ﬂavourings is regulated under Regulation (EC) No 1334/20081 of the European
Parliament and Council of 16 December 2008 on ﬂavourings and certain food ingredients with
ﬂavouring properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an
evaluation and approval are required for ﬂavouring substances.
The Union list of ﬂavourings and source materials was established by Commission Implementing
Regulation (EC) No 872/20122. The list contains ﬂavouring substances for which the scientiﬁc
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/20003.
On 5 July 2014, the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing
Aids (CEF) adopted an opinion on Flavouring Group Evaluation 226 (FGE.226): consideration of
genotoxicity data on one a,b–unsaturated aldehyde from chemical subgroup 1.1.1(b) of FGE.19.
The Panel concluded that for 4,5-epoxydec-2(E)-enal [FL-no: 16.071] of subgroup 1.1.1 b of
FGE.19, the Panel’s concern with respect to genotoxicity could not be ruled out and subsequently
additional data are requested.
On 9 January 2015, the applicant has submitted the ﬁnal study on plasma analysis on the above
mentioned substance [FL-no: 16.071] in relation to this EFSA evaluation.
1.1.1. Terms of Reference
The European Commission requests the European Food Safety Authority (EFSA) to evaluate this
new information on this new group of substances and, depending on the outcome, proceed to their
full evaluation in accordance with Commission Regulation (EC) No 1565/2000.
2. Data and methodologies
2.1. History of the evaluation of FGE.19 substances
Flavouring Group Evaluation 19 (FGE.19) contains 360 ﬂavouring substances from the EU Register
being a,b-unsaturated aldehydes or ketones and precursors which could give rise to such carbonyl
substances via hydrolysis and/or oxidation (EFSA, 2008a).
The a,b-unsaturated aldehyde and ketone structures are structural alerts for genotoxicity. The
Panel noted that there were limited genotoxicity data on these ﬂavouring substances but that positive
genotoxicity studies were identiﬁed for some substances in the group.
The a,b-unsaturated carbonyls were subdivided into subgroups on the basis of structural similarity
(EFSA, 2008a). In an attempt to decide which of the substances could go through the Procedure, a
(quantitative) structure–activity relationship (Q)SAR prediction of the genotoxicity of these substances
was undertaken considering a number of models (DEREKfW, TOPKAT, DTU-NFI-MultiCASE Models and
ISS-Local Models, (Gry et al., 2007)).
The Panel noted that for most of these models internal and external validation has been performed,
but considered that the outcome of these validations was not always extensive enough to appreciate
the validity of the predictions of these models for these a,b-unsaturated carbonyls. Therefore, the
Panel considered it inappropriate to totally rely on (Q)SAR predictions at this point in time and decided
not to take substances through the Procedure based on negative (Q)SAR predictions only.
The Panel took note of the (Q)SAR predictions by using two ISS Local Models (Benigni and Netzeva,
2007) and four DTU-NFI MultiCASE Models (Gry et al., 2007; Nikolov et al., 2007) and the fact that there
are available data on genotoxicity, in vitro and in vivo, as well as data on carcinogenicity for several
substances. Based on these data the Panel decided that 15 subgroups (1.1.1, 1.2.1, 1.2.2, 1.2.3, 2.1,
2.2, 2.3, 2.5, 3.2, 4.3, 4.5, 4.6, 5.1, 5.2 and 5.3) (EFSA, 2008a) could not be evaluated through the
1 Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on ﬂavourings and certain
food ingredients with ﬂavouring properties for use in and on foods and amending Council Regulation (EEC) No 1601/91,
Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34–50.
2 Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the list of ﬂavouring substances provided
for by Regulation (EC) No 2232/96 of the European Parliament and of the Council, introducing it in Annex I to Regulation (EC)
No 1334/2008 of the European Parliament and of the Council and repealing Commission Regulation (EC) No 1565/2000 and
Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p. 1–161.
3 Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an evaluation
programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8–16.
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Procedure due to concern with respect to genotoxicity. Corresponding to these subgroups, 15 FGEs were
established: FGE.200, 204, 205, 206, 207, 208, 209, 211, 215, 219, 221, 222, 223, 224 and 225.
For 11 subgroups, the Panel decided, based on the available genotoxicity data and (Q)SAR
predictions that a further scrutiny of the data should take place before requesting additional data on
genotoxicity from the ﬂavouring industry. These subgroups were evaluated in FGE.201, 202, 203, 210,
212, 213, 214, 216, 217, 218 and 220. For the substances in FGE.202, 214 and 218, it was concluded
that a genotoxic potential could be ruled out and accordingly these substances have been evaluated
using the Procedure. For all or some of the substances in the remaining FGEs, FGE.201, 203, 210, 212,
213, 216, 217 and 220, the genotoxic potential could not be ruled out.
To ease the data retrieval of the large number of structurally related a,b-unsaturated substances in
the different subgroups for which additional data are requested, EFSA has worked out a list of
representative substances for each subgroup (EFSA, 2008c). Likewise, an EFSA genotoxicity expert group
has worked out a test strategy to be followed in the data retrieval for these substances (EFSA, 2008b).
The ﬂavouring industry has been requested to submit additional genotoxicity data according to the
list of representative substances and test strategy for each subgroup.
The ﬂavouring industry has now submitted additional data and the present revision of FGE.226
concerns the evaluation of these data requested on genotoxicity.
2.2. History of the evaluation of FGE.226
The Flavouring Group Evaluation 226 (FGE.226) concerns the evaluation of the genotoxic properties
of one aliphatic aldehyde with the a,b-unsaturation in conjugation with an epoxide moiety. This
substance was originally allocated to FGE.200 (FGE.19 subgroup 1.1.1).
Subgroup 1.1.1 of FGE.19 originally covered 71 a,b-unsaturated aliphatic aldehydes. Seventy of
these are simple, aliphatic, a,b-unsaturated aldehydes, or precursors for such, with or without
additional double bonds, which is not in conjugation with the a,b-unsaturated structure. These 70
substances were allocated to subgroup 1.1.1(a) in FGE.200. The one remaining aliphatic, a,b-
unsaturated aldehyde contains an epoxide moiety which is not present within the other 70 members of
FGE.19 subgroup 1.1.1. On this basis, it would be anticipated to have different chemical reactivity
potential, and would have metabolic options that are not available to the other members of this
subgroup. For these reasons, the Panel decided that this substance should be allocated to a separate
subgroup, subgroup 1.1.1(b) and evaluated in a separate FGE, FGE.226.
The present revision of FGE.226 (FGE.226Rev1) deals with the evaluation of the genotoxicity data
submitted by the ﬂavouring industry for substance 4,5-epoxydec-2(trans)-enal [FL-no: 16.071] from subgroup
1.1.1(b).
FGE
Adopted by
EFSA
Link
No. of
substances
FGE.226 5 July 2012 http://www.efsa.europa.eu/en/efsajournal/pub/2838 1
FGE.226Rev1 4 May 2017 http://www.efsa.europa.eu/en/efsajournal/pub/4847 1
FGE: Flavouring Group Evaluation.
2.3. Presentation of the substances in ﬂavouring group evaluation 226
The Flavouring Group Evaluation 226 (FGE.226), corresponding to subgroup 1.1.1(b) of FGE.19,
concerns one aliphatic aldehyde with the a,b-unsaturation in conjugation with an epoxide moiety, 4,5-
epoxydec-2(trans)-enal [FL-no: 16.071]. These structural elements are considered to be structural
alerts for genotoxicity. The substance is shown in Table 1.
4,5-Epoxydec-2(trans)-enal [FL-no: 16.071] has previously been evaluated by the Joint FAO/WHO
Expert Committee on Food Additives (JECFA, 2006, 2009b). A summary of the current evaluation
status by JECFA and the outcome of the present consideration is presented in Appendix A, Table A.1.
As the a,b-unsaturated aldehyde and ketone structures are considered alerts for genotoxicity
(EFSA, 2008b) and the data on genotoxicity previously available did not rule out the concern for
genotoxicity, the Panel has requested additional genotoxicity data for 4,5-epoxydec-2(trans)-enal
according to the test strategy (EFSA, 2008b).
The ﬂavouring industry has submitted data requested by the Panel in FGE.226 that are evaluated in
the present revision of FGE.226 (FGE.226Rev1).
Section 2.4 of this opinion reports the same information that was presented in FGE.226 (EFSA CEF
Panel, 2012). Section 3 reports the evaluation of the new data submitted by industry.
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2.4. Genotoxicity data on 4,5-epoxydec-2(trans)-enal evaluated in
FGE.2264
The Industry has submitted in vitro and in vivo genotoxicity data for the representative and only
substance for this subgroup 1.1.1(b), 4,5-epoxydec-2(trans)-enal [FL-no: 16.071] (EFFA, 2011).
2.4.1. In vitro Data
In vitro genotoxicity assays have been performed in bacteria and mammalian cells with the a,b-
unsaturated aldehyde 4,5-epoxydec-2(trans)-enal [FL-no: 16.071].
2.4.1.1. Bacterial Reverse Mutation Assay
An Ames assay was conducted in Salmonella Typhimurium strains TA98, TA100, TA1535, TA1537
and TA102 to assess the mutagenicity of 4,5-epoxydec-2(trans)-enal, both in the absence and in the
presence of metabolic activation by phenobarbital and b-naphthoﬂavone induced rat liver S9-mix, in
two experiments (Sokolowski, 2001). It is a Good Laboratory Practice (GLP) study conducted in
accordance with OECD Test Guideline 471. An initial toxicity range-ﬁnding experiment was carried out
in the absence and presence of S9-mix in strains TA98 and TA100 only, using ﬁnal concentrations of
4,5-epoxydec-2(trans)-enal at 3, 10, 33, 100, 333 and 1,000 lg/plate, plus negative (solvent) and
positive controls. Evidence of toxicity, in terms of a decrease in revertant count, was apparent on all
plates treated at 333 lg/plate and above in the absence and at 1,000 lg/plate in the presence of S9-
mix. In the ﬁrst experiment, 4,5-epoxydec-2(trans)-enal [FL-no: 16.071] was tested in all ﬁve strains in
the absence and presence of S9-mix using plate incorporation methodology and ﬁnal concentrations of
either 1, 3, 10, 33, 100, and 333 lg/plate (TA1535, TA1537 and TA102 without S9-mix) or 3, 10, 33,
100, 333 and 1,000 lg/plate (TA1535, TA1537 and TA102 with S9-mix; TA100 and TA98 with and
without S9-mix). Following these treatments, evidence of toxicity was observed in all strains at
concentrations of 333 and/or 1,000 lg/plate, both in the absence and in the presence of S9-mix. No
strains produced a biologically signiﬁcant increase in the number of revertants.
In the second experiment, treatments of all the tester strains were performed in the absence and
presence of S9-mix using the same concentrations as in the ﬁrst experiment using the pre-incubation
methodology. Following these treatments, evidence of toxicity was observed in all strains at
concentrations of 333 and/or 1,000 lg/plate. No biologically signiﬁcant increases in the number of
revertants were seen in any strain (Appendix B, Table B.1).
Table 1: Speciﬁcation summary of the substance in the present group (JECFA, 2006, 2009a)
FL-no
JECFA-no
EU
register
name
Structural formula
FEMA no
CoE no
CAS no
Phys.
form
Mol.
formula
Mol.
weight
Solubility(a)
Solubility in
ethanol(b)
Boiling point, °C
Melting point, °C
ID test
Assay minimum
Refrac.
index(c)
Spec.
gravity(d)
16.071
1570
4,5-
Epoxydec-
2(trans)-
enal
4037
-
188590-62-7
Liquid
C10H16O2
168.23
Soluble
Soluble
80–83 (0.8 hPa)
IR NMR MS
87% (trans isomer)
and 8–10% (cis
isomer)
1.472–1.478
0.943–0.949
FL-no: FLAVIS number; JECFA: The Joint FAO/WHO Expert Committee on Food Additives; FEMA: Flavor and Extract Manufacturers Association;
CoE: Council of Europe; CAS: Chemical Abstract Service; ID: identity; IR: infrared spectroscopy; NMR: nuclear magnetic resonance; MS: mass
spectrometry.
(a): Solubility in water, if not otherwise stated.
(b): Solubility in 95% ethanol, if not otherwise stated.
(c): At 20°C, if not otherwise stated.
(d): At 25°C, if not otherwise stated.
4 Data presented in Section 2.4 are cited from the ﬁrst scientiﬁc opinion on FGE.226. These data are the basis for the
conclusions in FGE.226 requesting additional genotoxicity data. Only minor changes were made when the data were
reconsidered in FGE.226Rev1. However, this does not affect the conclusion that was drawn in FGE.226.
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It was concluded that 4,5-epoxydec-2(trans)-enal did not induce mutations in ﬁve strains of
S. Typhimurium when tested up to toxic concentrations in the absence and in the presence of a rat
liver metabolic activation system (Sokolowski, 2001).
2.4.1.2. Micronucleus Assays
4,5-Epoxydec-2(trans)-enal was assayed for the induction of chromosome damage, and potential
aneugenic effects, in mammalian cells in vitro by examining the effect on the frequency of micronuclei
in cultured human peripheral blood lymphocytes (whole blood cultures pooled from two healthy male
volunteers) treated in the absence and presence of rat liver metabolising system (S9-mix) (Lloyd,
2009). This GLP study complies with OECD Test Guideline 487. 4,5-Epoxydec-2(trans)-enal was added
at 48 h following culture initiation (stimulation by phytohaemagglutinin) either for 3 h in the absence
or presence of S9-mix, or for 24 h in the absence of S9-mix. Cytochalasin B (6 lg/mL) was added
either at the start of treatment (24-h treatments) or at the start of recovery (after 3-h treatments) in
order to block cytokinesis and generate binucleate cells for analysis. It remained in the cultures until
they were harvested 24 h after the start of treatment. A preliminary range-ﬁnding experiment had
been conducted with and without S9-mix treatment in order to determine the effect of treatment upon
replication index (RI), which was used as a basis for choosing a range of concentrations to be
evaluated in the main study.
In the main assay, micronuclei were analysed at multiple concentrations for each treatment group.
For 3-h treatment without S9-mix the concentrations were 1, 2, 4 and 5 lg/mL, for 3-h treatment with
S9-mix the concentrations were 9, 10.5 and 12 lg/mL, and for 24-h treatment without S9-mix the
concentrations were 2.5, 3, 3.5 and 4 lg/mL. The levels of cytotoxicity (reduction in RI) at the top
concentrations reached 61%, 52% and 55% in the 3-h treatment in the absence of S9-mix, the 3-h
treatment in the presence of S9-mix and the 24-h treatment in the absence of S9-mix, respectively.
These are within or very close to the target (50–60%) range. One thousand binucleate cells per
culture from two replicate cultures per concentration were scored for micronuclei. The study is
therefore considered to comply with OECD Test Guideline 487.
Following the 3-h treatment without S9-mix, there was an increase in the frequency of
micronucleated binucleate cells (MNBN) from 0.1% in the solvent control to 0.65% (p < 0.01) and
0.45% (p < 0.05) at the two highest concentrations. However, the increases observed at 4 and 5 lg/mL
were small and were ampliﬁed because the MNBN cell frequencies in both vehicle control cultures
(0.1% in both cases) were at the lower end of the normal range (0–1.0%). Furthermore, the MNBN
cell frequencies in all treated cultures under this treatment condition fell within the 95th percentile of
the normal range. Therefore, these observations were not considered by the authors of this study to
represent clear evidence of a biologically relevant response, although the results cannot be considered
clearly negative.
Following the 3-h treatment in the presence of S9-mix at the highest concentration analysed
(12 lg/mL), the frequency of MNBN cells (2.25%) was signiﬁcantly higher (p < 0.001) than those
observed in concurrent vehicle controls (0.2%). The MNBN cell frequencies in both cultures at 12 lg/mL
exceeded the normal ranges, and therefore, this was considered to be a positive result. Similarly, for
the 24-h treatment at the lowest (2.5 lg/mL) and two highest concentrations (3.5 and 4.0 lg/mL),
the frequencies of MNBN cells were signiﬁcantly higher (1.25% p < 0.05, 3.19% p < 0.001 and 3.80%
p < 0.001, respectively) than those observed in the concurrent vehicle control (0.65%). The MNBN cell
frequencies in both cultures at each of these concentrations exceeded the normal ranges, and
therefore, this was considered to be a positive result (Lloyd, 2009).
On the basis of these results, a new GLP study to determine whether 4,5-epoxydec-2(trans)-enal
was acting as a clastogen or an aneugen using ﬂuorescence in situ hybridisation (FISH) analysis was
attempted (Lloyd, 2011). Micronuclei were analysed at multiple concentrations for each treatment
group, and the maximum concentrations were based on the toxicity displayed in the previous study.
For 3-h treatment with S9-mix the concentrations were 0, 12, 15 and 17.5 lg/mL, with MNBN cell
frequencies of 0.30%, 0.20%, 0.50% and 0.45%, respectively, with historical control range of
0.0–0.7%. For 24-h treatment without S9-mix the concentrations were 0, 4, 5 and 7.5 lg/mL, with
MNBN cell frequencies of 0.35%, 0.25%, 0.55% and 0.20%, respectively, with a historical control
range of 0.1–0.9%. The levels of cytotoxicity (reduction in RI) were 16%, 36% and 48% for the three
concentrations in the 3-h treatment in the presence of S9-mix and 3%, 10% and 56% for the
three concentrations in the 24-h treatment in the absence of S9-mix, respectively. 48% and 56% at
the top concentrations are within or very close to the target (50–60%) range. One thousand
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binucleate cells per culture from two replicate cultures per concentration were scored for micronuclei.
The study is therefore considered to comply with OECD Test Guideline 487.
The MNBN cell frequencies in all cultures under both treatment conditions fell within the normal
range, thereby giving negative results (Appendix B, Table B.1). These data are in marked contrast to
the previously described study (Lloyd, 2009). However, the Panel noted that this study has a
shortcoming, i.e. in the absence of S9-mix, one replicate culture in the positive control vinblastine
resulted in an effect very close to the range of historical negative controls, which limits the reliability of
the outcome. Because no induction of micronuclei was observed following 3 + 21 h with S9-mix and
24 + 0 h without S9-mix treatments, further analysis (FISH) was not conducted. Different blood
donors were used in the ﬁrst and second studies on 4,5-epoxydec-2(trans)-enal. A subsequent study in
which peripheral blood from the donors used in both experiments were compared in a single
experiment conﬁrmed the existence of a donor effect for this compound (data not provided). It is not
known why this difference occurred, but the positive responses observed in the previous study (Lloyd,
2009) cannot be dismissed. The Panel considered the result of the negative study less reliable than the
positive one.
2.4.2. In vivo Data
2.4.2.1. In vivo Micronucleus Assays
On the basis of the in vitro micronucleus studies reported above, it was concluded that 4,5-
epoxydec-2(trans)-enal induced micronuclei in human lymphocytes and it was considered that the
most appropriate in vivo follow up was an in vivo micronucleus assay, in order to determine whether
the results obtained in the initial in vitro micronucleus assay could be conﬁrmed in vivo. Therefore,
groups of Han-Wistar rats were administered 4,5-epoxydec-2(trans)-enal via gavage and the induction
of micronuclei in the polychromatic erythrocyte (PCE) of the bone marrow of treated rats was
examined (Henderson, 2011).
In an initial range-ﬁnding experiment to identify a maximum tolerated dose (MTD), groups of male
and female (up to 3 animals/sex per group) Han-Wistar rats were administered 4,5-epoxydec-2(trans)-
enal by oral gavage at doses of 250, 350, 500, 700, 1,000, 1,400 and 2,000 mg/kg body weight (bw)
per day until an estimate of the MTD was established. Animals were dosed once daily for two
consecutive days with the test article and observations made over a 2-day period following the ﬁnal
administration. Clinical signs of toxicity and body weight were recorded. At doses of 500 mg/kg bw per
day and above, clinical signs of toxicity such as decreased activity and piloerection were observed in all
animals, and mortality was induced. At doses of 350 mg/kg bw per day and below no clinical signs of
toxicity were observed, except in one female at 350 mg/kg bw per day, for which decreased activity,
piloerection and hunched posture were observed. Both male and female groups at 350 mg/kg bw per
day showed mean body weight loss. On the basis of these concentrations, the MTD was considered to
be 350 mg/kg bw per day. Additionally, as there were no differences between sexes in apparent
toxicity, only male animals were subsequently used in the micronucleus experiment.
In the micronucleus experiment, groups of male (6 animals/group) rats were administered 4,5-
epoxydec-2(trans)-enal by oral gavage at 87.5, 175 and 350 mg/kg bw per day on two occasions 24 h
apart. Animals were sampled 24 h after the ﬁnal administration, thus enabling examination of cells
exposed to the test article over a period of 24–48 h prior to sampling. At the highest dose on day 2,
decreased activity was observed in all animals 1-h post-dose, and at 2-h post-dose, piloerection was
also noted in all animals. For the highest dose group, one animal was found dead at end of day 2.
However, there was no evidence of bone marrow exposure.
Rats treated with 4,5-epoxydec-2(trans)-enal at all doses exhibited group mean % PCE that were
similar to the vehicle control group. These values were comparable with the historical control data for
this experiment at the testing laboratory, thus conﬁrming there was no evidence of test article related
bone marrow toxicity. Additionally, rats treated with 4,5-epoxydec-2(trans)-enal at all doses exhibited
micronucleus (MN) PCE frequencies that were similar to the vehicle control group and which were
considered consistent with the laboratory’s historical data. There were no statistically signiﬁcant
increases in micronucleus frequency for any of the groups receiving the test article, compared to the
concurrent vehicle control (Appendix B, Table B.2). On this basis, it was concluded that 4,5-epoxydec-
2(trans)-enal did not induce micronuclei in the PCEs of the bone marrow of male rats treated up to
350 mg/kg per day (a dose which exceeded the MTD).
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2.4.3. Discussion of Genotoxicity Data
4,5-Epoxydec-2(trans)-enal did not induce gene mutations in a valid Ames test. In a valid in vitro
micronucleus assay, 4,5-epoxydec-2(trans)-enal was clearly positive in both treatments for 3 + 21 h in
the presence of S9-mix and for 24 + 0 h in the absence of S9-mix. In the same study, in the treatment
for 3 + 21 h in the absence of S9-mix, statistically signiﬁcant increases of MNBN cell frequencies were
reported at the two highest concentrations. These increases were not considered biologically relevant
because the MNBN cell frequencies in the vehicle control cultures (0.1%) were at the lower end of the
historical control range (0.0–1.0%) and because all the MNBN cell frequencies fell within the 95th
percentile of the normal range. On this basis, the results of this part of this study should be considered
as equivocal. Overall, the results of this study indicate that 4,5-epoxydec-2(trans)-enal is an in vitro
genotoxic agent both in the presence and in the absence of metabolic activation.
The positive results of the ﬁrst study (Lloyd, 2009) could not be conﬁrmed in a second study, in
which different blood donors were used (Lloyd, 2011). According to the study authors, the existence of
a donor effect for this substance was conﬁrmed in a subsequent study in which peripheral blood from
the donors used in both studies were compared in a single experiment. However, data related to this
experiment were not provided and also an explanation for this difference was not given. Therefore,
the concern for the genotoxic potential of 4,5-epoxydec-2(trans)-enal remains.
4,5-Epoxydec-2(trans)-enal was found negative in an in vivo micronucleus assay in rats treated by
oral gavage up to 350 mg/kg bw, considered as the MTD, on two occasions 24 h apart. At this dose
and below, no clinical signs of toxicity were observed, except one female; both male and female
groups showed only mean body weight loss. Clinical signs, including some mortality, were observed at
the dose of 500 mg/kg bw, used in the initial range-ﬁnding experiment. At 350 mg/kg bw, there was
no evidence of any test article-induced toxicity to the bone marrow. There was no proof that the bone
marrow was exposed. In addition, the negative results of this in vivo micronucleus assay do not allow
to exclude site of contact effects. Therefore, an in vivo Comet assay should be performed.
The request for a Comet assay is in line with the recommendations of the AFC Panel (EFSA, 2008b)
and Scientiﬁc Committee opinion on genotoxicity testing strategies applicable to food and feed safety
assessment (EFSA Scientiﬁc Committee, 2011).
2.4.4. Conclusion drawn in FGE.226
4,5-Epoxydec-2(trans)-enal did not induce gene mutations in bacterial cells (Ames test). It was
positive in an in vitro micronucleus assay in cultured human lymphocytes with and without metabolic
activation. Although these results could not be conﬁrmed in a second study in which different blood
donors were used, 4,5-epoxydec-2(trans)-enal is considered an in vitro genotoxic agent in the
presence and in the absence of S9-mix. The negative results obtained in an in vivo micronucleus assay
do not allow to exclude possible ﬁrst site of contact effects. In addition, there was no proof that the
bone marrow was exposed. On this basis, an in vivo Comet assay in rodents is required, in order to
verify possible genotoxic effects at the ﬁrst site of contact (e.g. stomach/duodenum cells) and in liver.
The request for a Comet assay is in line with the recommendations of the AFC Panel (EFSA, 2008b)
and Scientiﬁc Committee opinion on genotoxicity testing strategies applicable to food and feed safety
assessment (EFSA Scientiﬁc Committee, 2011).
3. Assessment of new data
Following the request for additional data expressed by the Panel in FGE.226, the industry has
investigated the presence of 4,5-epoxydec-2(trans)-enal [FL-no: 16.071] in the plasma of a satellite
group of animals from the in vivo micronucleus assay by Henderson, 2011 (Mallinson, 2014). The
industry has submitted an in vivo comet assay with scoring of duodenum and liver cells (Beevers,
2016). These additional data are evaluated in the present revision of FGE.226 (FGE.226Rev1).
3.1. Plasma bioanalysis
In order to demonstrate the bone marrow exposure of animals treated with 4,5-epoxydec-2(trans)-
enal [FL-no: 16.071] in the micronucleus assay by Henderson (2011) (see Section 2.4.2), a plasma
analysis of a satellite group of animals was provided. Six male Han-Wistar rats were dosed, by oral
gavage, with 350 mg/kg bw per/day of 4,5-epoxydec-2(trans)-enal [FL-no: 16.071]. A method was
developed for the analysis of 4,5-epoxydec-2(trans)-enal [FL-no: 16.071] using gas chromatography
with mass selective detection (GC-MSD) (Mallinson, 2014).
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According to the applicant, satisfactory linearity, recovery and repeatability were found for 4,5-
epoxydec-2(trans)-enal when the substance was spiked and analysed in rat plasma samples.
The Panel, however, noted that linearity in plasma extracts was in the range of 5–100 lg/mL, but
the highest concentration reported for 4,5-epoxydec-2(trans)-enal in rat plasma samples (0.14 lg/mL)
was far below this range. Moreover, the recovery and accuracy of the method were only determined
from 50 lg/mL and above. Therefore, the data of plasma analysis obtained in vivo are unreliable and
cannot be considered as demonstration of sufﬁcient bone marrow exposure (Appendix C, Table C.1).
3.2. In vivo Comet assay
4,5-Epoxydec-2(trans)-enal [FL-no: 16.071] was tested in an in vivo Comet assay in Han-Wistar rats
via oral gavage (Beevers, 2016). The dose-range ﬁnding test was not repeated because data from the
in vivo micronucleus study (Henderson, 2011) were used. Based on this study, the following doses
were selected: 75, 150 and 300 mg/kg bw per day. The study authors considered 300 mg/kg bw per
day as an estimate of the MTD (Beevers, 2016) because in the in vivo micronucleus study one animal
of the highest dose group (350 mg/kg bw per day) was found dead at the end of day 2 (Henderson,
2011). As no gender differences in toxicity, metabolism or bioavailability have been previously
identiﬁed, the study was conducted solely in male animals (6 animals/group). The vehicle control
group was dosed with 0.5% (w/v) aqueous methylcellulose (0.5% MC) and the positive control group
(3 animals) with ethyl methanesulfonate (EMS) 150 mg/kg bw per day. 4,5-Epoxydec-2(trans)-enal
and the vehicle control were given as two administrations, at 0 and 21 h; the positive control was
administered once only at 21 h. All animals were sampled at 24 h (Appendix C, Table C.1).
No clinical signs of toxicity were observed in animals following any treatments. A small but dose
related reduction in body weight gain, resulting in weight loss at the highest dose (300 mg/kg per
day) was observed. There was a generally dose-related decrease in albumin, and concomitant
decreases in total protein and albumin:globulin ratio in animals from all groups treated with [FL-no:
16.071]. A dose-related decrease in calcium and increase in phosphate in animals from all groups
given [FL-no: 16.071] were observed. There were marked increases in urea and creatinine in one
animal given 300 mg/kg per day. A small increase in urea was seen in several animals dosed with [FL-
no: 16.071] 150 or 300 mg/kg bw per day.
Macroscopically, stomach was gelatinous, thick, red, distended and/or contained abnormal contents
(clear ﬂuid) and duodenum was distended, pale and/or thick in animals from all groups. Jejunum and
ileum were distended and/or contained abnormal yellow gelatinous contents in animals given 300 mg/kg
per day. Caecum contained abnormal gritty contents in animals given 150 or 300 mg/kg per day and was
distended in one animal given 300 mg/kg per day.
Microscopically, in the duodenum, single cell necrosis and villous atrophy were present in animals
from all groups. There was a decrease in hepatocyte glycogen in animals from all groups given 4,5-
epoxydec-2(trans)-enal, with a dose-related effect.
In the Comet assay, treatment with 4,5-epoxydec-2(trans)-enal [FL-no: 16.071] did not cause
excessive tissue damage in the liver or duodenum which could interfere with the outcome of the
Comet assay as indicated by the lack of signiﬁcant increase in % hedgehogs that could have interfered
with the assay.
3.2.1. Comet assay in liver
Statistically signiﬁcant increases in tail intensity in the liver were observed following dose
administration at 75 mg/kg bw per day (p ≤ 0.05) and 300 mg/kg bw per day (p ≤ 0.01), no
statistically signiﬁcant increase was observed in the intermediate dose group (150 mg/kg per day).
However, a signiﬁcant linear trend was also apparent across the data (p ≤ 0.05).
The tail intensity values for all animals fell within the laboratory’s historical control data range (95%
reference ranges of 0.05–7.14%). However, this range is very wide. Additionally, considering tail
intensity data for the individual animals, the tail intensities of all animals in the highest dose group,
except one animal (tail intensity value of 0.38) are higher than the highest tail intensity value (tail
intensity value of 0.56) in the concurrent control group.
The clinical chemistry and histopathology data show no clear evidence of hepatotoxicity associated
with 4,5-epoxydec-2(trans)-enal treatment.
The Panel considered that the following two criteria for evaluation and interpretation of results as
positive (OECD TG 489) were fulﬁlled:
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a) at least one of the test doses exhibits a statistically signiﬁcant increase compared with the
concurrent negative control,
b) the increase is dose-related when evaluated with an appropriate trend test.
The third criterion (‘any of the results are outside the distribution of the historical negative control
data for a given species, vehicle, route, tissue, and number of administrations’) mentioned in the
OECD TG 489 is not applicable in this case because the range for historical negative controls is very
wide (95% reference range of 0.05–7.14%).
Therefore, the Panel concluded that 4,5-epoxydec-2(trans)-enal [FL-no: 16.071] is genotoxic in this
in vivo comet assay in the liver of rats.
3.2.2. Comet assay in duodenum
Group mean tail intensity and tail moment values in the duodenum for all groups of animals treated
with 4,5-epoxydec-2(trans)-enal were comparable with the group mean vehicle control data. There
were no statistically signiﬁcant differences in tail intensity between treated and control groups.
Therefore, the Panel concluded that 4,5-epoxydec-2(trans)-enal [FL-no: 16.071] is not genotoxic in the
duodenum of rats.
4. Conclusions
4,5-Epoxydec-2(trans)-enal [FL-no: 16.071] was negative in the Ames test both with and without
metabolic activation. However, positive effects of 4,5-epoxydec-2(trans)-enal were demonstrated in an
in vitro micronucleus assay both with and without metabolic activation. As an in vivo follow-up study, a
rat bone marrow micronucleus study was performed by gavage. The negative outcome of this study is
considered to be of limited relevance, because no clear indication of biological relevant exposure to the
target tissue could be demonstrated. Since the substance was positive in the in vitro micronucleus
assay both in the absence and in the presence of S9-mix, an in vivo Comet assay in the ﬁrst site of
contact (e.g. the duodenum) and in the liver was requested.
Comet assay data provided suggest that 4,5-epoxydec-2(trans)-enal [FL-no: 16.071] did not induce
DNA damage in the duodenum of rats treated up to 300 mg/kg per day by oral route (an estimate of
the MTD in male rats). However, the genotoxic effect observed in vitro was conﬁrmed in an in vivo
comet assay in the liver of rats.
Overall, the Panel concluded that 4,5-epoxydec-2(trans)-enal [FL-no: 16.071] does raise a safety
concern with respect to genotoxicity, and therefore, it cannot be evaluated according to the Procedure.
Additional remarks
The Panel noted that the petitioner suggested to consider in the evaluation that the exposure to
4,5-epoxydec-2(trans)-enal [FL-no: 16.071] is very low, based on the maximised survey-derived daily
intake (MSDI) approach (see Appendix D). However, the Panel considered that even if the exposure
would be below the threshold of concern for genotoxic carcinogens, such a comparison would only be
applicable to substances not intentionally added to foods, like impurities or contaminants.
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FLAVIS (FL) Flavour Information System (database)
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Appendix D – Exposure
D.1. Presence in food
According to the TNO database, the candidate substance [FL-no: 16.071] is not reported to be
present in natural food sources (Triskelion, 2017). However, there are authors reporting the presence
of the substance in processed and non-processed foods. Table D.1 reports a non-exhaustive list of
foodstuff containing 4,5-epoxydec-2(trans)-enal [FL-no: 16.071].
Table D.1: Examples of 4,5-epoxydec-2(trans)-enal occurrence in foodstuff
Food item Process Qualitative Quantitative Reference
Orange juice 1) Hand-squeezed
oranges
2) Juiced oranges with a
commercial juice
extractor model
Yes 1) Hinterholzer and
Schieberle (1998);
2) Mahattanatawee
et al. (2005)
Canned orange
juice
Canned orange juice
purchased in tin-coated steel
cans
Yes Ruiz Perez-Cacho et al.
(2007)
Peach a) Full ripe yellow-ﬂesh
peaches homogenised
b) Full ripe yellow-ﬂesh
peaches cut and
suspended in boiled
water
Yes Derail et al. (1999)
Grapefruit juice Hand-squeezed grapefruit Yes Buettner and Schieberle
(1999)
Whole milk
powder
Whole milk powder
purchased at domestic
markets; process not
speciﬁed
Yes Kobayashi and
Nishimura (2014)
Fresh rye bread
crumb
Fermentation and baking 4.5 lg/kg Kirchhoff and Schieberle
(2001)
Rye sourdough Fermentation 16 lg/kg (dry weight) Kirchhoff and Schieberle
(2002)Rye ﬂour Freshly ground rye ﬂour 0.5 lg/kg (dry weight)
French beans Raw beans and cooked
beans
Yes Hinterholzer et al.
(1998)
Mixed tomato-
onion puree
Heating Yes Koutidou et al. (2017)
Darjeeling black
tea extract
Tea leaves and tea infusion Yes Schuh and Schieberle
(2006)
Italian hazelnuts Raw hazelnuts and roasted
hazelnuts
Yes Burdack-Freitag and
Schieberle (2010)
Sunﬂower oil Oxidation Yes Guillen et al. (2005)
Extra virgin olive
oil
Sunﬂower oil
Virgin linseed oil
Heating at 190°C for several
hours
• Extra virgin olive oil up to
75.11  5.58 (lmol/L)
• Sunﬂower oil up to
186.21  15.24 (lmol/L)
• Virgin linseed oil up to
6.31  0.52 (lmol/L)
Guillen and Uriarte
(2012)
Corn oil Long-term storage at room
temperature with different
air–oil volume ratios and/or
air–oil contact surfaces
Yes Goicoechea and Guillen
(2014)
Cooked brown
rice
Boiling Yes Jezussek et al. (2002)
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D.2. Intended use and use levels as provided by the Flavour Industry
Use levels in the different food categories reported in Annex I of Reg. (EC) 1565/20005 have been
submitted by the ﬂavour industry and are reported in Table D.2 (EFFA, 2007).
Food item Process Qualitative Quantitative Reference
Buttermilk Fresh fermented sweet-
cream buttermilk and stored
sour-cream buttermilk
Yes Helier and Schieberle
(1997)
Egg yolk Heating Yes Cemy and Guntz (2004)
Roasted sesame
oil
Roasting Yes Cadwallader and Heo
(2001)
Boiled cod Boiling Yes Milo and Grosch (1997)
popcorn Freshly popped Yes Rengarajan and Seitz
(2003)
Ripened anchovy Ripening Yes Triqui and Guth (1997)
5 Commission Regulation (EC) No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an
evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8–16.
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D.3. Intake data from intended use
Annual production volumes of the ﬂavouring substance as surveyed by industry are used to
calculate the ‘Maximised Survey-derived Daily Intake’ (MSDI) assuming that the production ﬁgure only
represents 60% of the use in food, due to underreporting and that 10% of the total EU population are
consumers (SCF, 1999).
Use levels for 4,5-epoxydec-2(trans)-enal [FL-no: 16.071] provided by industry (EFFA, 2007) and
listed in Table D.3, have been used to calculate the ‘modiﬁed Theoretical Added Maximum Daily Intake’
(mTAMDI).6
The MSDI and mTAMDI exposure estimates are given in Table D.4.
Table D.4: Exposure to 4,5-epoxydec-2(trans)-enal [FL-no: 16.071]
FL-no Name
EU MSDI lg/capita
per day
mTAMDI lg/person
per day
16.071 4,5-Epoxydec-2(trans)-enal 0.04(a) 0.69(b)
FL-no: FLAVIS number; MSDI: maximised survey-derived daily intake; mTAMDI: modiﬁed theoretical added maximum daily
intake.
(a): Based on EU poundage of 0.3 kg (EFFA, 2016).
(b): Based on use levels data from 2007 (EFFA, 2007).
6 mTAMDI estimation is based in an approach used by the SCF up to 1995 (SCF, 1995) and is calculated on the basis of standard
portions and normal use levels for ﬂavoured beverages and foods in general, with exceptional levels for particular foods.
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